Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That ...

Revance Therapeutics accepts Crown Laboratories' $3.65/share acquisition offer over rival bid from Teoxane, ending battle for ...

EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...

Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...

Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...

All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after more than three years of receiving treatment, researchers wrote in a Nature paper ...

Bristol Myers Squibb cuts 67 jobs in Lawrence Township, NJ, while Kyowa Kirin lays off 52 employees at Princeton facility, per NJ WARN notices.

Despite uncertainty around HPV vaccine sales in China, Merck CEO Robert Davis said he’s confident the company can “deliver ...

Astellas is reorganizing its management team, and while it doesn't involve a change at the top as Daiichi Sankyo announced ...

China tensions, following US restrictions on Chinese rivals BGI and MGI. Illumina says China accounts for 7% of Q3 revenue.